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De novo mutations in PLXND1 and REV3L cause
Mo¨bius syndrome
Laura Tomas-Roca1,2, Anastasia Tsaalbi-Shtylik3, Jacob G. Jansen3, Manvendra K. Singh4,5, Jonathan A. Epstein4,
Umut Altunoglu6, Harriette Verzijl7, Laura Soria1, Ellen van Beusekom1, Tony Roscioli1,8, Zafar Iqbal1,
Christian Gilissen1, Alexander Hoischen9, Arjan P.M. de Brouwer1, Corrie Erasmus7, Dirk Schubert10,
Han Brunner1,11, Antonio Pe´rez Ayte´s12, Faustino Marin2, Pilar Aroca2, Hu¨lya Kayserili6, Arturo Carta13,
Niels de Wind3, George W. Padberg7 & Hans van Bokhoven1
Mo¨bius syndrome (MBS) is a neurological disorder that is characterized by paralysis of the
facial nerves and variable other congenital anomalies. The aetiology of this syndrome has
been enigmatic since the initial descriptions by von Graefe in 1880 and by Mo¨bius in 1888,
and it has been debated for decades whether MBS has a genetic or a non-genetic aetiology.
Here, we report de novo mutations affecting two genes, PLXND1 and REV3L in MBS patients.
PLXND1 and REV3L represent totally unrelated pathways involved in hindbrain development:
neural migration and DNA translesion synthesis, essential for the replication of endogenously
damaged DNA, respectively. Interestingly, analysis of Plxnd1 and Rev3l mutant mice shows
that disruption of these separate pathways converge at the facial branchiomotor nucleus,
affecting either motoneuron migration or proliferation. The ﬁnding that PLXND1 and REV3L
mutations are responsible for a proportion of MBS patients suggests that de novomutations in
other genes might account for other MBS patients.
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M
o¨bius syndrome (MBS) (MIM 157900) is a rare
congenital cranial dysinnervation disorder character-
ized by non-progressive facial palsy and impairment of
ocular abduction, due to paralysis or weakness of the facial (n7)
and abducens (n6) nerves, and frequently other cranial nerves1–6.
Both intrauterine environmental factors and genetic causes have
been proposed for the aetiology and pathogenesis of MBS. A
disruption of blood vessel migration during development, which
can be secondary to misoprostol7 or cocaine8 exposure during
pregnancy, has been hypothesized to lead to hindbrain hypoxia,
resulting in cranial nerve dysfunction9. A limited number of
familial cases with an atypical manifestation of MBS have been
reported10–13. In addition, a founder mutation in HOXB1 has
been associated with an autosomal recessive form of an MBS-like
syndrome, with limited phenotypic overlap with typical MBS14.
However, the vast majority of patients has a sporadic occurrence
with a very low recurrence risk for siblings. This is consistent with
either the involvement of environmental factors or with
dominant de novo mutations as the underlying mechanism15.
The broad spectrum of neuropathological and neuroradiolo-
gical ﬁndings suggests that MBS is due to a developmental defect
of the entire rhombencephalon16,17, rather than an isolated
cranial nerve disruption. This is in contrast to hereditary
congenital facial palsy (HCFP), which is characterized by the
isolated dysfunction of the facial nerve. Two HCFP loci have been
identiﬁed: HCFP1 (MIM 601471) at chromosome 3q21-q22
(ref. 18) and HCFP2 (MIM 604185) at chromosome 10q21.3-
q22.1 (ref. 19). Extensive studies have been conducted to explain
the HCFP phenotype and to pave the way for genetic studies in
MBS, but analysis of genes in the HCFP1 and HCFP2 loci,
including the prime candidate gene PLXND1 at chromosome
3q21-q22 (ref. 20), has so far not identiﬁed any causative
mutations in HCFP and in MBS patients21.
In this study we undertake exome sequencing of two case–
parent trios and six isolated patients with classical MBS to
investigate the possibility of an underlying genetic cause. We
identify de novo mutations in ﬁve different genes. For two of these
genes, PLXND1 and REV3L, additional de novo mutations in other
MBS patients are identiﬁed. The causality of de novo PLXND1 and
REV3L mutations for the neuropathological features of MBS is
further supported by analysis of the respective knockout mice.
Strikingly, for both heterozygous mutants we observe hypoplasia of
the facial branchiomotor nucleus, which is consistent with the
facial nerve weakness in MBS patients. Taken together, the present
data establish de novo mutations as a cause for MBS, providing a
rationale for exome sequencing in patient–parent trios to identify
de novo mutations in other genes underlying MBS.
Results
Identiﬁcation of de novo mutations by exome sequencing. We
excluded all variants inherited from either parent in the two trios
under the hypothesis of de novo mutations as the underlying cause
of MBS (Supplementary Table 1). Two de novo variants were
detected in patient 1 (P1) (Fig. 1a; reported previously17), one in
the SPO11 gene (c.712T4C; p.Cys238Arg; NM_012444) and the
other in the PLXND1 gene (c.5685C>A; p.Asn1895Lys;
NM_015103) (Fig. 1a,b; Supplementary Fig. 1; Supplementary
Tables 2 and 3). SPO11 is involved in meiotic recombination, and
targeted disruption of this gene in mice results in fertility
problems22, but no features related to MBS. The occurrence of a
de novo mutation in PLXND1 was more consistent with a role for
this gene in MBS, given that PLXND1 was previously considered a
strong candidate for HCFP1 and MBS20,21. Trio-exome sequencing
in patient 2 did not reveal any de novo variant. A different
analytical approach was taken for the six patients with isolated
MBS and this was to Sanger sequence all candidate variants
identiﬁed in the exome studies (Supplementary Tables 1 and 4).
Sanger sequencing conﬁrmed de novo variants, identiﬁed by exome
sequencing, in IFT172, CCDC160 and REV3L, in three unrelated
patients. The de novo missense mutation in the IFT172 gene
(NM_015662) identiﬁed in patient 3 (Fig. 1; Supplementary
Tables 2 and 3) is unlikely to be causative for the MBS phenotype,
because biallelic mutations are associated with the unrelated Jeune
and Mainzer-Saldino Syndromes in humans23. The de novo variant
in the X-chromosomal CCDC160 gene of patient 4 (P4) (a male) is
a c.501delA frameshift mutation in exon 2 (NM_001101357)
(Supplementary Fig. 1; Supplementary Tables 2 and 3). Patient 5
(P5; Fig. 1c) carries a de novo variant in REV3L, c.1096þ 1G4A,
affecting the canonical donor splice site in exon 10 (NM_002912)
(Fig. 1d; Supplementary Fig. 1, Supplementary Tables 2 and 3).
Aberrant splicing products were identiﬁed by quantitative reverse
transcriptase–PCR analysis of REV3L messenger RNA obtained
from Epstein-Barr virus-transformed lymphoblastoid cell lines
(EBV-LCLs) of patient P5. Sequencing of these products revealed
aberrant REV3L transcripts lacking either exon 9 or exons 9 and
10, in addition to decreased levels of normal REV3L transcript
(Supplementary Fig. 2).
Additional de novo mutations in the PLXND1 and REV3L.
Next, we screened CCDC160, PLXND1 and REV3L by Sanger
sequencing in a cohort of 103 MBS patients, including some HCFP
patients who were not previously tested for PLXND1
(ref. 21). The screening identiﬁed four additional de novo
mutations in unrelated patients, two affecting PLXND1 and two
affecting REV3L (Fig. 1; Supplementary Fig. 1; Supplementary
Tables 2 and 3). The PLXND1 mutations were identiﬁed in
patients P9 (c.4454_4455GC4CA; p.Arg1485Pro) and P10
(c.3018C4T; p.Leu1006Leu). The mutation in P9 affects a con-
served arginine residue in the GTPase-activating protein domain of
the protein. The silent mutation in P10 is at a leucine residue in the
IPT/TIG domain (immunoglobulin-like fold, plexins, transcription
factors/transcription factor immunoglobin) that is characteristic
for plexin proteins24. The two additional de novo mutations in
REV3L were identiﬁed in patients P11 and P12. A de novo
missense mutation c.1160A4G was identiﬁed in patient P11,
predicting an amino-acid substitution p.Glu387Gly. In addition,
patient P12 carried a nonsense mutation (c.2662A4T; p.Lys888*),
which is predicted to result in a loss-of-function allele.
The absence of PLXND1, REV3L and CCDC160 truncating
variants in NHLBI Exome Sequencing Project (ESP; http://
evs.gs.washington.edu/EVS/) and a low residual variant intoler-
ance score for these genes of  1.30 (4.88th percentile),  2.1
(1.55th percentile) and 0.014 (54.98th percentile), respectively, are
consistent with PLXND1, REV3L and CCDC160 being intolerant
to loss-of-function mutations25. The amino acids that are
affected by the missense variants in REV3L and PLXND1
are highly conserved throughout evolution (p.Glu387Gly (P11),
p.Asn1895Lys (P1), p.Arg1485Pro (P9) and p.Leu1006Leu (P10))
(Supplementary Fig. 3).
The probability of identifying multiple de novo mutations in the
same gene in a cohort of 103 individuals was calculated using the
Poisson test and is 0.0001217 for REV3L (P value¼ 2.4 10 4)
and 9.34e 05 for PLXND1 (P value¼ 1.8 10 4). The presence
of a mutation in the other allele in these patients was excluded by
sequencing the coding exons of PLXND1 and REV3L. Screening
of CCDC160 gene in our cohort of male MBS patients did not
reveal additional de novo mutations.
PLXND1 deﬁciency affects neural ﬁbres’ structures. PLXND1
encodes a protein of 521 amino acids and is a member of the
plexin family of proteins. Plexins bind to semaphorins (Semas), a
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large family of extracellular, secreted and membrane proteins26,27.
PLXND1 is expressed in the vascular system20 and in speciﬁc
structures of the central nervous system, such as the cranial and
spinal ganglia, the cortical plate, the external granular layer of
the cerebellum, the striatum and in dendritic cells28–30.
Sema3E/PlexinD1 signalling is involved in the development of
two descending forebrain tracts, the corticofugal and the
striatonigral tracts31. To determine the effect of deﬁciency of
PLXND1 in central nervous system development, we compared
morphologic structures of the embryonic brain of wild-type (wt),
heterozygous and homozygous PlexinD1 knockout mice at
E16.5 (ref. 32). Histological comparison of the three genotypes
revealed consistent hypoplasia of the corpus callosum, anterior
commissure and fasciculus retroﬂexus in Plxnd1 / mice
(Fig. 2a). These three brain structures are bundles of neural
ﬁbres that connect brain areas. Both the corpus callosum and the
anterior commissure allow interhemispheric communication,
whereas the fasciculus retroﬂexus links the forebrain with the
midbrain.
Plxnd1 mutant mice show a defect of neuronal migration.
The facial nerve phenotype in Plxnd1 heterozygous and
homozygous mice was investigated. Analogous to observations in
brain autopsies of an MBS patient3, we observed a signiﬁcant
decrease in the number of motoneurons in the facial
branchiomotor nucleus in homozygous mice as compared with
wt mice (Unpaired t-test P value¼ 0.0049; Fig. 2b). The
development of the cranial nerve undergoes a complex
migration within the rodent hindbrain33 (Fig. 2c). Between
E10.5 and E14.5, neurons in rhombomere 4 (r4) start migrating
tangentially along the ventral midline, reaching r5 and r6.
Then they migrate dorsally until the alar/basal plate
boundary and begin to migrate radially to their ﬁnal
destination in the pial surface of r6 (refs 33–35). To trace the
nature of the decreased neuronal density of the FBM, we carried
out an immunohistochemical analysis using the motoneuron-
speciﬁc molecular marker Islet-1 in brains from E16.5 embryos
(Fig. 2d). In line with this migration pattern, all FBM
motoneurons reached r6 at E16.5 in wt mice (Fig. 2d). In sharp
contrast, in all of the Plxnd1þ / and Plxnd1 / mutant mice, a
subpopulation of motoneurons was still located in r4 and r5 at
E16.5. Collectively, these results support a causative role of a
defect in motoneuron migration caused by a heterozygous Plxnd1
mutation akin to the de novo PLXND1 mutations in MBS patients
P1, P9 and P10.
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Figure 1 | Clinical features of Mo¨bius syndrome patients and de novo mutations in PLXND1 and REV3L. (a) Clinical features of the patients carrying the
mutations in PLXND1 (P1, P9 and P10). Patient P1 shows an impairment of ocular abduction in a relaxed facial position; she is not able to smile and she
cannot close her eyes completely. Patient P9 in a relaxed facial position presents left upper facial paralysis. Patient P10 showing bilateral facial paralysis,
inability to close his mouth and lagophthalmos. (b) Genomic structure of the PLXND1 gene and the PLXND1 protein structure and the position of
de novo mutations. The different protein domains are depicted. GAP, GTPase-activating protein; IPT/TIG, immunoglobulin-like fold, plexins, transcription
factors/transcription factor immunoglobin; D1-PBM, PDZ-binding motif; MET, mesenchymal–epithelial transition. (c) Clinical features of the patients
carrying the mutations in REV3L (P5, P11 and P12). Patient P5 in a relaxed position, showing the characteristic inability of MBS patients to smile in the
second photograph. Both eyes show incomplete closure. There is agenesis of the left pectoralis muscle (Poland variant) and absence of digits from the left
hand. Patient P11 has both eyes ﬁxed in straight position and a complete deﬁciency of both abduction and adduction. There is a complete inability to follow
objects laterally. Furthermore, a bilateral facial nerve palsy is present producing a lagophthalmos on eye closure in both eyes, and oral rim asymmetry with
an inability to smile. Patient P12 in a relaxed facial position. The ability to smile of P12 has been improved following plastic surgery at age of 13 years.
Inappropriate closure of both eyes is still present. (d) Schematic structure of human REV3L gene (left) and REV3L protein (right). MBS-associated
mutations detected in three patients (P5, P11 and P12) are indicated. The coloured bands represent the known domains of the protein. Rev7-binding domain,
site of binding of the heterodimeric Rev3l partner Rev7; ZF, zinc ﬁnger.
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Rev3l heterozygous mice show hypoplasia of neural structures.
The human REV3L protein acts as the catalytic subunit of DNA
polymerase z, a key protein in replication of endogenously or
exogenously damaged DNA36,37. Consistent with the phenotypes
of the Rev3l heterozygous mice, in situ hybridization data show
that Rev3l is highly expressed in the developing embryonic
brain around mid-gestation (Supplementary Fig. 4). Biallelic
inactivation of Rev3l in mice leads to mid-term embryonic
lethality. Rev3l-deﬁcient mouse embryos display pleiotropic
morphological abnormalities, but are invariably growth-retarded
and display massive apoptosis, notably of the brain36. Analysis of
the subarachnoid space at E16.5 in Rev3lþ / mice revealed a
highly signiﬁcant increase in subarachnoid volume (t-test,
P value¼ 0.0047; Fig. 3a). In addition, Rev3l heterozygous mice
at P0 showed signiﬁcantly reduced hindbrain volumes as
compared with wt (t-test, P value¼ 0.015; Fig. 3b). We then
analysed the facial motor nucleus at P0 (Fig. 3c,d). In contrast to
the Plxnd1 mutant mice, there was no evidence for a motoneuron
migration defect in the Rev3l heterozygous embryos. Nevertheless,
there was a strong decrease in the number of motoneurons in
Rev3l heterozygous embryos (t-test, P valueo0.0001; Fig. 3d).
These data provide strong support for hypoplasia of the motor
nucleus consequent to a heterozygous Rev3l mutation, similar as
the REV3L mutation in MBS patients P5, P11 and P12.
Rev3l mutant MEFs displayed increase of DNA damage. The
essential role of Rev3l in replication of damaged DNA has been
extensively studied in vitro and in Rev3l-deﬁcient cells and
mice36–39. We wondered whether the neuronal defects in MBS
patients and Rev3l heterozygous mice reﬂect partial replication
defects at DNA carrying endogenous DNA lesions. To this aim,
we analysed responses of immortalized Rev3l mutant mouse
embryonic ﬁbroblasts (MEFs) to Benzo[a]pyrene diolexpoxide
(BPDE), an agent that induces DNA damage that mimics bulky
endogenous nucleotide lesions. Rev3l heterozygous MEFs
displayed a slight, but signiﬁcant, decrease in cell survival
(Fig. 4a). To substantiate the effect of haploinsufﬁciency, we
measured replication of BPDE-damaged DNA in these cells and
found that Rev3l heterozygous cells displayed a slight but
signiﬁcant defect, suggesting the presence of replication stress
(Fig. 4b, right panel). Since replication stress induces DNA
damage-signalling cascades that initiate cellular senescence or
apoptosis, we measured phosphorylation of the signalling
proteins Rpa, Chk1 and H2AX (Fig. 4c)40. Remarkably, the
Rev3l heterozygous cells displayed a level of DNA damage
signalling that was almost as high as in Rev3l-deﬁcient cells.
These data suggest that, in Rev3l heterozygous mice, marginally
under-replicated endogenous DNA lesions induce strong DNA
responses, contributing to the observed neuronal phenotypes.
Discussion
We have identiﬁed de novo mutations in PLXND1 and REV3L in
six unrelated sporadic MBS patients. The neuropathological
alterations and other clinical ﬁndings in MBS patients correlate to
those in the Plxnd1 and Rev3lmutant models. Thus, hypoplasia of
the facial motor nucleus that was observed in both mouse models
has also been documented in MBS patients3,16. In addition,
several developmental anomalies that were previously reported in
Plxnd1 knockout mice are mirrored in patients carrying a
PLXND1 mutation, as well as other MBS patients. For example,
craniofacial bone abnormalities observed in Plxnd1 knockout
mice41,42 were also seen in patients P1 and P9, and which are
commonly seen in other MBS patients17 (Supplementary
Table 5). In addition, the vertebral defects in Plxnd1 mutant
mice are reminiscent of the scoliosis in patient P1, and the
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Figure 2 | Plxnd1 mouse brain characterization. (a) Parafﬁn sagittal
sections of embryonic mouse brains processed with Nissl staining at E16.5.
These two pictures are medial sections of a view of the corpus callosum
(CC), the anterior commisure (ac) and the fasciculus retroﬂexus (rf). These
three structures appear hypoplastic in Plxnd1 / mice. Scale bars,
500mm. (b) Graphic representation of the number of motoneurons in facial
motor nucleus in wt, heterozygous and homozygous Plxnd1 knockout
(mean±s.d.). Unpaired t-test was used to calculate the P value¼0.0049
(N¼ 5). (c) Schematic representation of the facial nerve migratory process
along the hindbrain. The motoneuron migratory pathway is indicated with a
red arrow. The rhombomeres (r3–r11) boundaries are marked with a line.
Cb, cerebellum; FBM, facial motor nucleus; SpC, spinal cord. The upper part
in (d) shows the immunohistochemical staining of facial FBM motoneurons
with anti-Islet-1 antibody (dark brown). The rhombomere units (r3–r7) are
marked with a dashed line. Black arrows point the motoneurons migration
across the rhombomeres in the heterozygous and the homozygous Plxnd1
knockout mouse. The area of the facial motor nucleus is marked by the
square. Scale bar, 300mm. A detailed view of the facial motor nucleus and
motoneurons migration is shown in the lower part of d. Motoneurons
appear outside the facial nucleus along the migratory path of the facial
nerve in both the heterozygous and the homozygous genotypes. Scale bar,
100mm. All reported P values tested were calculated by the unpaired t-test
using Graphpad software.
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haemorrhages seen in Plxnd1 mutant mouse resemble the facial
haemangiomas seen in patient P1 (Supplementary Table 5).
A possible causative de novo mutation was also identiﬁed in
CCDC160. No PLXND1-coding mutations were identiﬁed in
HCFP1 families, although their genetic defect maps to the
PLXND1 locus20, suggesting the presence of regulatory mutations
affecting the spatiotemporal expression of PLXND1 during
embryonic brain development.
The clinical features of patients with heterozygous PLXND1
and REV3L mutations are highly variable with no obvious
genotype–phenotype correlations. While the variable phenotype
of patients P1, P5 and P9–P11 are consistent with the clinical
criteria for MBS6,43, patient P12, who was identiﬁed as having a
heterozygous nonsense mutation in REV3L, only had bilateral
facial paralysis and no weakness of the abducens nerves,
suggestive of the restricted HCFP phenotype (Fig. 1;
Supplementary Table 5). Thus, our data show that MBS and
HCFP can be allelic conditions. In contrast to P12, the phenotype
of patient P5, who was identiﬁed as having a heterozygous
loss-of-function splice-site mutation in REV3L, presented with a
wide range of features in addition to the cranial nerve palsies,
including absence of digits on the left hand, Poland
anomaly, hearing loss and cardiac defect. This variability is
highly reminiscent of the variable phenotype of completely
Rev3l-deﬁcient embryos. Rev3l deﬁciency may result in a
stochastic ablation of cell lineages during embryonic
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Figure 3 | Morphological analysis of the brains of Rev3l embryonic and newborn mice. (a) Example of a sagittal section of the embryonic mouse head at
E16.5 stage used for subarachnoid volume rendering, processed with Nissl staining. The subarachnoid space is shown in green. Scale bar, 1mm. Right:
subarachnoid volume rendering measures of both genotypes. In all Rev3l heterozygous embryos the subarachnoid space is signiﬁcantly increased as
compared with wt embryos (Unpaired t-test P value¼0.0047, N¼ 5). Scale bar, 500mm (b) Example of one of the hindbrain sagittal sections at P0 used
for hindbrain volume rendering. We measured the volume of ﬁve wt and ﬁve heterozygous mice. The hindbrain boundaries are indicated by dashed lines.
Scale bar, 500mm. Right: Rev3l heterozygous mice show a signiﬁcant decrease of hindbrain volume (Unpaired t-test P value¼0.015, N¼ 5).
(c) Lateral hindbrain sections at the P0 stage of a view of the facial motor nucleus, inside the square. Scale bar, 300mm. (d) Higher magniﬁcation of the
facial motor nucleus showing paucity of Rev3l heterozygous motoneurons. Scale bar, 100mm. Right: quantiﬁcation of motoneurons in the facial motor
nucleus, in each side of the hindbrain, in ﬁve wt and ﬁve heterozygous P0 mice (mean±s.d.). The difference is statistically highly signiﬁcant (Unpaired
t-test P valueo0.0001, N¼ 10). We do not show both genotypes because there are no visible differences between them. 5N, trigeminal nucleus; 7N, facial
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0.05 was considered to be statistically signiﬁcant (*). P values smaller than 0.01 (**) or 0.001 (***) were considered highly signiﬁcant.
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development36. On the basis of these and our current data, it is
conceivable that the spectrum of MBS symptoms reﬂects the
stochastic loss of neuronal precursors, caused by replicative stress
at endogenous DNA lesions and consequent DNA damage
responses, during embryonic development. Likewise, the variable
clinical presentation that is seen for PLXND1 mutations might be
due to similar stochastic disruptions of motoneuron migration to
the FBM nucleus.
Exome sequencing has detected causative de novo mutations in
two (or three including the CCDC160 mutation) in the initial
cohort of eight MBS patients. This result is of general interest, as
several studies have suggested previously that vascular disruptions
during the ﬁrst trimester of pregnancy rather than genetic
mechanisms are the leading cause of MBS5–7,44. While vascular
disruptions caused by various teratogens can explain the MBS
phenotype in some patients, our current data indicate that exome
sequencing in parent–patient trios is a powerful approach for
identifying causative mutations in MBS. It is to be expected that
whole-genome sequencing will deliver an even higher yield when
focusing on de novo mutations in coding and noncoding
regions45. That only three de novo mutations were identiﬁed in
PLXND1 and three in REV3L in our cohort suggests a low
frequency of mutations in these genes as a cause of MBS,
implying genetic heterogeneity and intrauterine insults as
causative events in other MBS patients. We expect that the
implementation of whole-exome sequencing and whole-genome
sequencing of parent–patient trios in a diagnostic setting will
further dissect the aetiology of MBS.
Methods
Patients. We identiﬁed eight isolated Mo¨bius patients in this study. They were the
only affected individuals in their families. These patients (patients 1–8) were
selected from a cohort of patients with the pathognomonic signs of MBS6,43: facial
and abducens palsy17. Clinical details of these patients and other patients carrying
de novo mutations (P9, P10, P11 and P12) are given in the Supplementary Table 5
and in Fig. 1a. Informed consent was obtained from all the subjects involved in this
study, and all procedures were in accordance with the ethics of the World Medical
Association Declaration of Helsinki. Ethical approval for the reported studies
was obtained from the Medical Ethical Committee Arnhem-Nijmegen, from the
University of Parma, the University of Istanbul and University Hospital LA FE,
Valencia.
Whole-exome sequencing. Exome sequencing was performed on DNA from
peripheral blood, using the SureSelect Human All Exon v2 50Mb Kit (Agilent,
Santa Clara, CA) followed by multiplexed analysis on a SOLiD 4 System sequen-
cing slide (Life Technologies, Carlsbad, CA) as described previously46. Colour
space reads were mapped to the hg19 reference genome with the SOLiD BioScope
version 1.3 software, which utilizes an iterative mapping approach. Sequence
analyses from all the patients are summarized in Supplementary Table 4. Statistical
single-nucleotide variants were subsequently called by the Di-Bayes algorithm with
high call stringency. Called variants were combined and annotated with a custom
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Figure 4 | Survival, replication of bulky DNA lesions and DNA damage signaling in Rev3l-mutated MEF lines. (a) Survival of wt (þ /þ ), Rev3l
heterozygous (þ / ) and Rev3l-deﬁcient ( / ) MEF lines after mock exposure, or after exposure to Benzo(a)pyrene diolepoxyde (BPDE). Rev3l heterozygous
MEFs are slightly sensitive to BPDE indicating haploinsufﬁciency. Experiments were performed in triplicate. Error bars, s.e.m. The asterisks indicate a signiﬁcant
difference between the wt and the heterozygous lines (unpaired t-test, Po0.05). (b) Representation of replication fork progression after exposure to BPDE, or
mock exposure. Rev3l heterozygous MEFs display normal fork progression at undamaged DNA (mock treated, left panel), but a marginal defect in replication of
bulky lesion-containing DNA (BPDE, right panel). Error bars, s.e.m. (c) Immunoblots to detect the phosphorylation of DNA damage-signalling markers upon
treatment with BPDE. g-H2AX: phosphorylated histone H2AX. RpaS4/8-P: 32 kDa subunit of single-stranded DNA-binding protein Rpa, phosphorylated at Ser 4
and/or Ser 8. Total levels of Rpa are somewhat variable consequent to slight differences in proliferation rate between the lines. Chk1S354-P Checkpoint kinase-1,
phosphorylated at Ser 354. b-actin: loading control. Rev3l-heterozygous MEFs display DNA damage signalling that is almost as strong as Rev3l-deﬁcient MEFs.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8199
6 NATURE COMMUNICATIONS | 6:7199 |DOI: 10.1038/ncomms8199 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
analysis pipeline. The total number of variants identiﬁed in each patient are
summarized in Supplementary Table 1. Of these variants, some were located in the
exonic sequences or located in canonical splice sites, deﬁned as the dinucleotides
up- and downstream of exonic sequence (Supplementary Table 1).
Under the hypothesis of de novo mutations as the underlying cause of MBS
syndrome, we excluded all variants inherited from either parent in the two trios
(Supplementary Table 1). From the remaining variants in these two patients, we
excluded all synonymous variants, as well as variants present in (single-nucleotide
polymorphism database) dbSNP (v138) or in our in-house-sequenced exome
database (5,031 exomes), and variants in noncoding regions with the exception of
canonical splice-site sequences. Manual inspection of mapped reads excluded
additional, likely false positive, variants. After Sanger sequencing, only two variants
were validated de novo mutations in one of the trios.
The approach for the six isolated cases was slightly different. For these, we
applied a ﬁltering scheme excluding variants observed in dbSNP (v138) and in our
in-house database (5,031 exomes (Supplementary Table 1). We further analysed all
truncating variants, missense variants with a PhyloP score 43 or those affecting
genes with a possible involvement in MBS, as suggested by the gene ontology term
or mouse mutant phenotype. Candidate variants were validated by Sanger
sequencing, and parental DNAs were tested for de novo occurrence of the
respective variant (Supplementary Tables 2 and 3).
The reference gene sequences referred to in this study are available in the
RefSeq database under the following accession code: PLXND1, NM_015103;
REV3L, NM_002912; CCDC160, NM_001101357; SPO11, NM_012444 and
IFT172, NM_015662.
Mutation analysis. Primer sequences were designed using Primer3 software
(http://frodo.wi.mit.edu/) encompassing the candidate variants. To exclude
additional changes in either REV3L, PLXND1 or CCDC160, we designed primers
for the ampliﬁcation of all exons and intron–exon boundaries of REV3L (Genbank
ID NM_002912), PLXND1 (Genbank ID NM_015103) and CCDC160 (Genbank
ID NM_NM_001101357). Sequences of primers are shown in Supplementary
Table 6. PCR was performed on 50 ng of genomic DNA with Taq DNA polymerase
(Invitrogen, Carlsbad, CA). A nucleofast 96 PCR plate (Clontech Lab, Mountain
View, CA) was used to purify the PCR amplicons, according to the manufacturer’s
protocol. Sequence analysis was performed with the ABI PRISM Big Dye Termi-
nator Cycle Sequencing V3.1 ready Reaction Kit and the ABI PRISM 3730 DNA
Analyzer (Applera Corp, Foster City, CA). PCR products were sequenced by
Sanger sequencing and analysed using Vector NTI software (Life Technologies).
Cell culture. EBV-LCL cells from patient P5 and ﬁve controls were cultured to a
density of 0.5 106 cells per ml. After incubation for 4 h at 37 C, cells were
harvested by centrifugation at 200g for 5min at room temperature, washed once
with PBS, pelleted by centrifugation at 200g for 5min at room temperature and
snap frozen in liquid nitrogen. MEFs were obtained from E13.5-day-old embryos
of intercrossed Rev3þ / , p53þ / mice. The embryos were ﬁnely minced,
trypsinized and the resulting MEFs were cultured in DMEM supplemented with
10% fetal calf serum and antibiotics until spontaneous immortalization47.
First-strand synthesis. EBV-LCL cells were harvested by centrifugation at 6,000g
at room temperature. RNA isolation was performed using the NucleoSpin RNA kit
(Qiagen, Hilden, Germany) according to the manufacturer’s protocols. RNA was
reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad Laboratories,
Hercules, CA, USA) according to the manufacturer’s protocol. Complementary
DNA (cDNA) was puriﬁed with NucleoSpin extract II (Qiagen) according to the
manufacturer’s protocol.
Quantitative PCR (QPCR) analysis. SYBR green-based real-time QPCR
expression analysis was performed on an Applied Biosystem Fast 7,500 System
machine. Primer sequences around exon 10 were designed using Primer3 software
(http://frodo.wi.mit.edu/) (Supplementary Table 6). Primers encompassed at least
one boundary between two exons. GUSB was used as a reference gene48. QPCR
quantiﬁcations were performed in duplicate on the equivalent of 5 mg of total
RNA from the ﬁrst-strand synthesis and included a water control. Experimental
threshold cycles (Ct) values were within the range of cDNA dilutions used to
validate the primers. The melt curves of all PCR products showed a single PCR
product. All water controls were negative. Differences in expression of the REV3L
alleles were calculated by the comparative Ct or 2DDCt method49. The P value
was derived from the standard score (Z-value) as compared with the normal
distribution of the ﬁve controls. We used an a-level of 0.05, because only one gene
was assessed.
Reverse transcriptase–PCR. cDNA from patient 1 EBV-LCLs and one control
were used to amplify REV3L. The ﬁrst pair of primers was designed
surrounding the canonical splice-site mutation (c.1096þ 1G4A) in exon 10, and a
control pair of primers was designed within exon 14 (see Supplementary Table 6).
Mouse breeding. Plxnd1 heterozygous mice were maintained on a C57BL/6
background and mated to generate Plxnd1 knockout and heterozygous embryos
(male and female) for analysis. Plxnd1 null and wt mouse embryos (E16.5)
were harvested from timed matings. Noon was designated E0.5. Embryos were
genotyped as described32. All Plxnd1 mouse work was performed according to the
University of Pennsylvania animal care guidelines.
C57BL/6 wt, Rev3l heterozygous and Rev3l-deﬁcient mice and embryos were
described before36. C57Bl/6 Rev3l heterozygous mice were mated to generate male
and female embryos and newborn mice for analysis. Rev3l heterozygous and wt
mouse embryos (E16.5) were derived from timed matings. Noon was designated
E0.5. Embryos were genotyped as described36. Mice were treated using Federation
of Laboratory Animal Science Associations (FELASA) standards and mouse
experiments were performed under permit DEC 11108 from the animal experiment
committee of the Leiden University Medical Center.
Mouse tissue preparation. Seven Plxnd1 wt, seven Plxnd1 heterozygous and
seven Plxnd1 homozygous embryos at E16.5 (stage corroborated according to
Theiler50) were killed and brains were dissected in PBS at room temperature and
ﬁxed in 4% paraformaldehyde at 4 C overnight. The next day, brains were washed
in PBS, dehydrated in ethanol and stored at  20 C. Brains were processed for
parafﬁn and agarose embedding and sectioned into 16- and 90-mm slices using a
microtome and vibratome, respectively.
We analysed two different stages to compare phenotypic aberrations. Five wt
and ﬁve Rev3l heterozygous embryos at E16.5 (stage corroborated according to
Theiler50) and ﬁve wt and ﬁve Rev3l heterozygous P0 newborn pups were killed
and ﬁxed by immersion in phosphate-buffered 4% paraformaldehyde (0.1M;
pH 7.4) at 4 C for 24 h. Fixed brains and heads were embedded in parafﬁn and
they were sectioned into 16-mm slices using a microtome.
Tissue staining. Seven Plxnd1 wt, seven Plxnd1 heterozygous and seven Plxnd1
homozygous embryos at E16.5, ﬁve Rev3l wt and ﬁve Rev3l heterozygous embryos
at E16.5 (stage corroborated according to Theiler50) and ﬁve Rev3l wt and ﬁve
Rev3l heterozygous P0 newborn pups were embedded in parafﬁn, sectioned and
were stained with Nissl stain according to routine protocols51.
Immunohistochemistry. Two Plxnd1 wt, two Plxnd1 heterozygous and two
Plxnd1 homozygous embryos were embedded in agarose and processed for
immune histochemistry with the Islet-1 antibody (catalogue number 39.4D5)
obtained from the Developmental Studies Hybridoma Bank (University of Iowa,
Iowa City). Sections were washed in PBS and then treated with 0.1% hydrogen
peroxide in PBS for 1 h in the dark to inactivate endogenous peroxidase activity.
After several rinses in PBT (PBS with 0.2% Triton X-100), sections were blocked
with 0.5% goat serum, 0.2% BSA and 0.2% Triton X-100 (Sigma, St Louis, MO,
USA) in PBS for 4 h and then incubated overnight at 4 C with monoclonal
antibody anti-Islet-1 (1:50 in blocking solution). Subsequently, sections were
incubated with biotinylated goat anti-mouse secondary antibody (1:300,
2 h incubation; BA-9200, Vector Laboratories, Burlingame, CA, USA), and then
with streptavidin/horseradish peroxidase complex (1:200, 2 h incubation; PK-4000,
Vectastain-ABC kit; Vector Laboratories). All antibodies were diluted in the same
blocking solution as the primary antibody. The histochemical detection of the
peroxidase activity was carried out using 0.03% diaminobenzidine and 0.005%
H2O2. After immunoreaction, the sections were mounted, dehydrated and then
coverslipped with Eukitt (Fluka, Buchs, Switzerland).
Quantiﬁcation of motoneurons. We counted the total number of motoneurons
presents in the facial motor nucleus in parafﬁn sagittal sections processed with
Nissl staining. We used ﬁve Plxnd1 wt, ﬁve Plxnd1 heterozygous and ﬁve Plxnd1
homozygous mice at E16.5 and ﬁve Rev3l wt and ﬁve Rev3l heterozygous P0
newborns, and we counted separately the number of motoneurons from the right
and left hindbrain sides (around 12 sections each side) (20–25 slices total per
animal). For the counting we used the open-source ImageJ Cell Counter software52.
Differences in the number of motoneurons between the heterozygous, homozygous
and the wt mice were calculated by a comparative t-test, using Graphpad Software
(http://graphpad.com/quickcalcs/ttest1.cfm).
Brain structures volume rendering. We performed volume rendering of image
stacks on serial light microscopic sections of 16 mm using the open-source ImageJ
TrakEM2 (ref. 53). For the volume rendering of the subarachnoid space around
100 sagittal slices of each of the ﬁve Rev3l wt and ﬁve Rev3l heterozygous mice at
E16.5 were used. This embryonic stage was selected because the calciﬁcation of the
cranial bones is not completed yet allowing the sectioning. For hindbrain volumes
comparison, around 80 slices of each of the ﬁve Rev3l wt and ﬁve Rev3l
heterozygous brains at P0 were used. After alignment of all images from each brain
respectively, we highlighted the areas of interest in each section to measure their
volumes. The boundaries of the hindbrain were delineated according to the Allen
Developing Mouse Brain Atlas from rhombomere r1 until r11, including the
cerebellum.
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Survival assay. Rev3l survival assays were conducted with Rev3lþ /þ , Rev3lþ /
and Rev3l / MEFs. In each well of a six-well plate, 0.5 106 exponentially
growing cells were seeded in MEF medium (DMEM supplemented with 10% fetal
calf serum, glutamax and antibiotics) and cultured overnight. Then, the cells were
exposed to 0–300 nM BPDE (Biochemical Institute for Environmental Carcino-
gens, Grosshansdorf, Germany) that was dissolved in anhydrous tetrahydrofuran
(THF, Sigma-Aldrich) for 60min in serum-free medium at 37 C. The cells were
trypsinized and seeded in MEF medium at clonal densities in 9-cm dishes. After
culturing for 12–14 days at 37 C, cell clones were ﬁxed, stained with methylene
blue and the number of cell clones was counted (n¼ 3). The number of clones after
mock treatment was set at 100%. The data were obtained with two and three
independent Rev3þ /þ and Rev3þ / MEF lines, respectively, and one Rev3 /
MEF line.
Replication progression assay. Progression of replicons using the Alkaline DNA
unwinding assay was determined following seeding of 5 104 exponentially
growing cells per well in a 24-well plate and culturing overnight in MEF medium at
37 C. The cells were mock treated with the solvent THF or exposed to 500 nM
BPDE in serum-free medium for 15min at 37 C. The medium was removed, cells
were washed once with 150mM NaCl and pulse labelled with [3H]thymidine
(2mCiml 1; 76 Cimmol 1) in MEF medium for 15min at 37 C. MEF medium
with radioactive thymidine was removed and the cells were cultured in MEF
medium supplemented with 10 mM cold thymidine. At different times after pulse
labelling, the local unwinding of DNA ends of elongating replication forks, the
separation of single-stranded DNA and double-stranded DNA (dsDNA) using
hydroxylapatite columns and the determination of radioactivity in the fractions
containing single-stranded DNA and dsDNA was performed47 (n¼ 3). The
percent of maturation of replicons was calculated by the following equation:
(radioactivity in dsDNA/total radioactivity) 100%. The data were obtained
with single Rev3þ /þ and Rev3 / MEF lines and two Rev3þ / MEF lines.
Western blotting. In each well of a six-well plate, 2.5 105 exponentially growing
cells were seeded in MEF medium and cultured overnight. Then, the cells were
mock treated with the solvent THF or exposed to 500 nmol BPDE for 15min in
serum-free medium at 37 C. After rinsing the cells with PBS, cells were cultured in
MEF medium. At different times after treatment, up to 12 h, cells were lysed using
Laemmli buffer. The proteins were separated by SDS–polyacrylamide gel electro-
phoresis and blotted onto nitrocellulose membranes (Hybond-C extra; Amersham
Biosciences). The membranes were incubated overnight at 4 C with antibodies
speciﬁc for gH2AX (S129) (mouse monoclonal; Millipore; cat. no. 05-0636;
dilution 1:1,000), phosphorylated Chk1 (at serine 345; rabbit polyclonal; Cell
Signaling; cat. no. 2348; dilution 1:1,000), phosphorylated Rpa32 (at serines 4/8;
rabbit polyclonal; Bethyl; cat. no. A300-245A; dilution 1:1,000), total Rpa (rat
polyclonal; Cell Signaling; cat. no. 2208; dilution 1:1,000) and b-actin (mouse
monoclonal; Oncogene; cat. no. CP01; dilution 1:20,000). After incubation with
appropriate secondary antibodies conjugated to peroxidase (Bio-Rad), proteins
were visualized using enhanced chemoluminescence detection. Uncropped scans
with indicated size markers are shown in Supplementary Fig. 5.
Statistical analysis. The probability of ﬁnding two mutations in a cohort of 103 in
each gene was calculated by the Poisson test. We took into account the presence of
two alleles and estimated gene mutation rates based on recent exome sequencing
data54. Moreover, a conservative Bonferroni correction was done for multiple
testing.
Statistical signiﬁcance of differences in motoneuron counts between the wt mice
and the mutant mice were determined by the unpaired t-test. The signiﬁcance of
differences of the hindbrain volume and subarachnoid space between the Rev3l
heterozygous and the wt mice was calculated by the comparative t-test. Signiﬁcance
in sensitivities of MEF lines to BPDE and in replication fork progression after
exposure to BPDE was determined using the unpaired t-test, s¼ 0.90. A P value
smaller than 0.05 was considered to be statistically signiﬁcant (*), and P values
smaller than 0.01 (**) or 0.001 (***) were considered highly signiﬁcant.
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